NurrOn Pharmaceuticals, INC.
5:00 PM - 5:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders.
NurrOn is focused on discovering and developing innovative treatments that have the potential to improve clinical outcome in PD patients. The greatest unmet medical need in PD is to slow or prevent disease progression. Through targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, we aim to develop a paradigm changing PD treatment to improve patients' quality of life.
NurrOn is focused on discovering and developing innovative treatments that have the potential to improve clinical outcome in PD patients. The greatest unmet medical need in PD is to slow or prevent disease progression. Through targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, we aim to develop a paradigm changing PD treatment to improve patients' quality of life.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
ATH-399A for Parkinson's disease
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
